Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

ASCO 2019

American Society of Clinical Oncology Annual Meeting
Chicago, 31st May – 4th June

The American Society of Oncology (ASCO) 2019 Annual Meeting was held in Chicago, IL, from 31 May – 4 June. A world-renowned faculty discussed state-of-the-art treatment modalities, ongoing controversies in the field, and the latest data.

Hot topics at this year’s meeting included the rise of precision medicine, immunotherapy, disparities in care, and therapies that are emerging. Updates from the latest clinical trials were received, including data from the PROSPER, CANFOUR, FIERCE-22 and CLEOPATRA studies.

Bladder Cancer

View all
3:45
FIERCE-22 trial: vofatamab with pembrolizumab for urothelial carcinoma
Arlene Siefker-Radtke
2:57
Immune-checkpoint inhibitors for urothelial cancer
Petros Grivas • 2 Jun 2019

Breast Cancer

View all
1:27
TNBC: the targeted therapy era
Adam Brufsky • 2 Jun 2019
1:29
The genetics of breast cancer complete response
Sandra Swain • 3 Jun 2019

Lung Cancer

View all
0:59
Biggest obstacles in lung cancer therapy
Roy Herbst • 2 Jun 2019
1:04
Tepotinib: advanced non-small cell lung cancer
Paul Paik

Prostate Cancer

View all
4:28
PSMA vs AXUMIN PET/CT in prostate cancer
Jeremie Calais
2:24
PEACE III: radium-223 vs. enzalutamide for mCRPC
Bertrand Tombal • 1 Jun 2019

Skin Cancer

View all
2:34
KEYNOTE-029: pembrolizumab with ipilimumab for melanoma
Georgina Long • 2 Jun 2019
1:18
Stage IV melanoma: Frontline options
Paolo Ascierto • 3 Jun 2019

Gynecological Cancer

View all
1:30
DIRVA: intratumorally injected durvalumab for cervical cancer
Gemma Kenter • 2 Jun 2019
2:49
Immunotherapy priming with neo-antigens
Thomas Helleday
The content of VJOncology is intended for healthcare professionals